Mergers & Acquisitions
Adicon and Seller Terminate Crown Bioscience Purchase as Regulatory Approvals Miss Deadline
By News Desk ·
Key takeaways
- Adicon Holdings and the seller mutually terminated the Crown Bioscience share purchase agreement effective November 13, 2026.
- The deal, agreed in November 2025, would have transferred Crown Bioscience from JSR Life Sciences to Adicon for US$204 million.
- Adicon's board expects no material adverse impact on the group's business operations or financial position.
Adicon Holdings terminated its planned purchase of 100% of Crown Bioscience International after regulatory approvals were not obtained by an extended deadline, ending a deal agreed at US$204 million. The future of trading reported the termination on November 16, 2026.
Adicon and Seller End the Crown Bioscience Agreement
Adicon Holdings and the seller mutually terminated the share purchase agreement effective November 13, 2026. The termination followed the failure to secure regulatory approvals by the extended deadline, according to the report.
The agreement had been struck in November 2025, when JSR Life Sciences entered a definitive agreement to transfer Crown Bioscience to Adicon Holdings Limited, an entity affiliated with The Carlyle Group, for US$204 million, with closing scheduled for 2026, according to akta.pro company records.
Crown Bioscience is a global contract research organization headquartered in San Diego that provides preclinical and translational oncology services to pharmaceutical and biotechnology companies. The company was founded in 2006 and its records list a headcount range of 1,001 to 5,000.
Adicon's board expects no material adverse impact on the group's business operations or financial position from the termination.
Crown Bioscience's Research Platform and Partnerships
The same records describe Crown Bioscience's global PDX model database of 2,500+ patient-derived xenograft models, which it calls the world's largest commercial PDX collection. Its organoid models database using HUB protocols includes over 600 specialized in vitro models with associated PDXO data, and 500+ matched PDXO-PDX models span 22 cancer types.
Crown Bioscience and Turbine formed a strategic partnership in April 2026 to integrate Turbine's AI-driven in silico Virtual Assays with Crown's tumor organoid assays based on HUB Organoid Technology. In September 2025, Medicines Discovery Catapult and Crown Bioscience formed a strategic global alliance for radiopharmaceutical innovation.
Other Deals in the Sector
A-CAP said on November 13, 2026 that it remained in discussions with Palmetto Heritage over a potential acquisition of Atlantic Coast Life and Southern Atlantic, and that it disagreed with AM Best's downgrades.
Willdan Group completed a $285 million acquisition of Mantis Innovation, a deal reported on November 12, 2026 that expands its energy efficiency platform.